Skip to main content
Erschienen in: Pediatric Nephrology 8/2018

28.04.2018 | Brief Report

Metabolite diagnosis of primary hyperoxaluria type 3

verfasst von: Lawrence Greed, Frank Willis, Lilian Johnstone, Sharon Teo, Ruth Belostotsky, Yaacov Frishberg, James Pitt

Erschienen in: Pediatric Nephrology | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Primary hyperoxaluria type 3 (PH3) is a recently described cause of childhood renal calculi. It results from mutations in the HOGA1 gene and most cases have been diagnosed after clinical ascertainment, exclusion of other genetic hyperoxalurias and mutation testing. Metabolite testing has not been widely applied but holds promise for the rapid screening and diagnosis of patients who are not specifically suspected to have PH3.

Case-Diagnosis/Treatment

Two cases presented with renal calculi. Urine metabolite testing by tandem mass spectrometry was performed as part of the routine diagnostic work-up for this condition. Both had significantly increased levels of the PH3 urine marker 4-hydroxyglutamate and related metabolites. The diagnosis of PH3 was confirmed by the finding of bi-allelic damaging HOGA1 mutations.

Conclusions

Urine screening by tandem mass spectrometry is a rapid, high-throughput test that can detect PH3 cases that may otherwise not be diagnosed.
Literatur
1.
Zurück zum Zitat Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, Monico CG, Feinstein S, Ben-Shalom E, Magen D, Weissman I, Charon C, Frishberg Y (2010) Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 87:392–399CrossRefPubMedPubMedCentral Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, Monico CG, Feinstein S, Ben-Shalom E, Magen D, Weissman I, Charon C, Frishberg Y (2010) Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 87:392–399CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS (2011) Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 6:2289–2295CrossRefPubMedPubMedCentral Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS (2011) Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 6:2289–2295CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Belostotsky R, Pitt JJ, Frishberg Y (2012) Primary hyperoxaluria type III—a model for studying perturbations in glyoxylate metabolism. J Mol Med (Berl) 90:1497–1504CrossRef Belostotsky R, Pitt JJ, Frishberg Y (2012) Primary hyperoxaluria type III—a model for studying perturbations in glyoxylate metabolism. J Mol Med (Berl) 90:1497–1504CrossRef
4.
Zurück zum Zitat Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT (2012) 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta 1822:1544–1552CrossRefPubMedPubMedCentral Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT (2012) 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta 1822:1544–1552CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Ben-Shalom E, Frishberg Y (2015) Primary hyperoxalurias: diagnosis and treatment. Pediatr Nephrol 30:1781–1791CrossRefPubMed Ben-Shalom E, Frishberg Y (2015) Primary hyperoxalurias: diagnosis and treatment. Pediatr Nephrol 30:1781–1791CrossRefPubMed
6.
Zurück zum Zitat Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC, Rare Kidney Stone C (2015) Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26:2559–2570CrossRefPubMedPubMedCentral Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC, Rare Kidney Stone C (2015) Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26:2559–2570CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Allard L, Cochat P, Leclerc AL, Cachat F, Fichtner C, De Souza VC, Garcia CD, Camoin-Schweitzer MC, Macher MA, Acquaviva-Bourdain C, Bacchetta J (2015) Renal function can be impaired in children with primary hyperoxaluria type 3. Pediatr Nephrol 30:1807–1813CrossRefPubMed Allard L, Cochat P, Leclerc AL, Cachat F, Fichtner C, De Souza VC, Garcia CD, Camoin-Schweitzer MC, Macher MA, Acquaviva-Bourdain C, Bacchetta J (2015) Renal function can be impaired in children with primary hyperoxaluria type 3. Pediatr Nephrol 30:1807–1813CrossRefPubMed
8.
Zurück zum Zitat Feldkötter M, Wei AZ, Langman CB, Ventzke A, Hoppe B (2014) Urinary hydroxy-oxo-glutarate (HOG) as diagnostic factor for primary hyperoxaluria type 3 [abstract SA-OR087]. Annual Scientific Meeting of the American Society of Nephrology. Journal of the American Society of Nephrology, Philadelphia, USA, p 100A Feldkötter M, Wei AZ, Langman CB, Ventzke A, Hoppe B (2014) Urinary hydroxy-oxo-glutarate (HOG) as diagnostic factor for primary hyperoxaluria type 3 [abstract SA-OR087]. Annual Scientific Meeting of the American Society of Nephrology. Journal of the American Society of Nephrology, Philadelphia, USA, p 100A
9.
Zurück zum Zitat Pitt JJ, Willis F, Tzanakos N, Belostotsky R, Frishberg Y (2015) 4-hydroxyglutamate is a biomarker for primary hyperoxaluria type 3. JIMD reports 15:1–6PubMed Pitt JJ, Willis F, Tzanakos N, Belostotsky R, Frishberg Y (2015) 4-hydroxyglutamate is a biomarker for primary hyperoxaluria type 3. JIMD reports 15:1–6PubMed
10.
Zurück zum Zitat Clifford-Mobley O, Hewitt L, Rumsby G (2016) Simultaneous analysis of urinary metabolites for preliminary identification of primary hyperoxaluria. Ann Clin Biochem 53:485–494CrossRefPubMed Clifford-Mobley O, Hewitt L, Rumsby G (2016) Simultaneous analysis of urinary metabolites for preliminary identification of primary hyperoxaluria. Ann Clin Biochem 53:485–494CrossRefPubMed
11.
Zurück zum Zitat Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ, Sikora P, Mache C, Pohl M, Stahl M, Toenshoff B, Pape L, Fehrenbach H, Jacob DE, Grohe B, Wolf MT, Nurnberg G, Yigit G, Salido EC, Hoppe B (2013) Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur J Hum Genet 21:162–172CrossRefPubMed Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ, Sikora P, Mache C, Pohl M, Stahl M, Toenshoff B, Pape L, Fehrenbach H, Jacob DE, Grohe B, Wolf MT, Nurnberg G, Yigit G, Salido EC, Hoppe B (2013) Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. Eur J Hum Genet 21:162–172CrossRefPubMed
12.
Zurück zum Zitat Pitt JJ, Eggington M, Kahler SG (2002) Comprehensive screening of urine samples for inborn errors of metabolism by electrospray tandem mass spectrometry. Clin Chem 48:1970–1980PubMed Pitt JJ, Eggington M, Kahler SG (2002) Comprehensive screening of urine samples for inborn errors of metabolism by electrospray tandem mass spectrometry. Clin Chem 48:1970–1980PubMed
Metadaten
Titel
Metabolite diagnosis of primary hyperoxaluria type 3
verfasst von
Lawrence Greed
Frank Willis
Lilian Johnstone
Sharon Teo
Ruth Belostotsky
Yaacov Frishberg
James Pitt
Publikationsdatum
28.04.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 8/2018
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-018-3967-6

Weitere Artikel der Ausgabe 8/2018

Pediatric Nephrology 8/2018 Zur Ausgabe

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.